Physician profile
John Ogden
NPI 1851823389
$2,710.29
in general payments reported to CMS, 2019-2025
30 companies · $605 in 2025
The $605 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $405 · 2021: $478 · 2022: $433 · 2023: $500 · 2024: $289 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.61 |
| Education | $144.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $539.71 | 2020-2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $200.92 | 2020-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $137.83 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.70 | 2020-2025 | Fruzaqla |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $124.27 | 2025 | Libtayo |
| Blueprint Medicines Corporation | $115.24 | 2022-2024 | Ayvakit |
| Seagen INC. | $96.23 | 2021 | |
| Sobi, INC | $91.86 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $90.95 | 2023 | |
| Merck Sharp & Dohme LLC | $86.43 | 2023-2025 | Keytruda, Lynparza |
| Adaptive Biotechnologies Corporation | $86.10 | 2020-2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $85.02 | 2023-2025 | |
| Acrotech Biopharma INC. | $79.25 | 2021-2022 | |
| Stryker Corporation | $72.03 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.97 | 2022-2024 | |
| Janssen Biotech, INC. | $69.69 | 2023-2025 | Erleada, Rybrevant, Akeega |
| Karyopharm Therapeutics INC. | $68.70 | 2021-2024 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $64.99 | 2020 | |
| Celgene Corporation | $61.69 | 2024-2025 | Reblozyl |
| Genentech USA, INC. | $54.26 | 2023-2025 | Polivy, Lunsumio |
| Genzyme Corporation | $49.25 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $48.40 | 2023-2025 | |
| Acera Surgical, INC. | $31.87 | 2025 | Restrata Wound Matrix |
| Pfizer INC. | $30.65 | 2025 | |
| Caris Mpi, INC. | $29.19 | 2025 | Mi Cancer Seek |
| Amgen INC. | $22.56 | 2021 | |
| Dova Pharmaceuticals | $19.91 | 2021 | |
| Morphosys, US INC. | $15.19 | 2023 | Monjuvi |
| Abbvie INC. | $14.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.